1 active not recruiting, 1 completed. 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Cerevance: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications CVN424 75 mg, CVN424 150 mg, Placebo - Parkinson Disease | Phase 3 | Active not recruiting | Cerevance | 330 | 2024-09-20 | 2026-04-17 |
| Phase 1 SAD/MAD Study of CVN766 in Healthy Volunteers CVN766 - Safety Issues, Tolerance | Phase 1 | Completed | Cerevance | 64 | 2022-01-17 | 2024-11-04 |
Australia (2) · Czechia (1) · France (1) · Italy (1) · Poland (1) · Puerto Rico (1) · Spain (1) · United Kingdom (1) · United States (1)